Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Amylyx Pharmaceuticals Inc AMLX

Healthcare
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company... see more

Recent & Breaking News (NDAQ:AMLX)

AMYLYX PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLX

PR Newswire March 29, 2024

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX

Newsfile March 29, 2024

Levi & Korsinsky Reminds Amylyx Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLX

Accesswire March 29, 2024

AMLX LAWSUIT ALERT: Levi & Korsinsky Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Accesswire March 29, 2024

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx

PR Newswire March 29, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - AMLX

Newsfile March 29, 2024

Amylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO(R) ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint - Hagens Berman

Newsfile March 29, 2024

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) Shareholders

PR Newswire March 29, 2024

Levi & Korsinsky Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLX

Accesswire March 29, 2024

IMPORTANT APRIL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire March 29, 2024

Levi & Korsinsky Reminds Amylyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLX

Accesswire March 29, 2024

Amylyx Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX

Accesswire March 29, 2024

IMMINENT AMLX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit!

Accesswire March 29, 2024

Levi & Korsinsky Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLX

Accesswire March 28, 2024

AMYLYX PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLX

Accesswire March 28, 2024

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100k to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX

Newsfile March 28, 2024

Lost Money on Amylyx Pharmaceuticals, Inc.(AMLX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Accesswire March 28, 2024

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders

Accesswire March 28, 2024

Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX

Accesswire March 28, 2024

Amylyx Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX

Accesswire March 28, 2024